Treatment insights
Exact results. Actionable insights. Personalized cancer care. Our portfolio of genomic and genetic tests informs personalized treatment paths across early and advanced stages as well as proactive decisions for inherited forms of cancer.
PREDICTING CHEMOTHERAPY BENEFIT IN HR+, HER2- EARLY BREAST CANCER
The Oncotype DX Breast Recurrence Score® test is the only genomic test proven to predict a patient’s individual benefit from chemotherapy.4, 5
ADVANCED CANCER TREATMENT SELECTION
OncoExTraTM is an ultra-comprehensive genomic test that uses DNA and RNA to identify clinically actionable alterations and any associated therapies or clinical trials—delivering your patient’s complete genomic story in one streamlined report. Not available in all countries.
HEREDITARY CANCER RISK ASSESSMENT
RiskguardTM is a pan-cancer Hereditary Cancer Test that identifies germline variants that may impact clinical decision-making in breast, prostate, colorectal, ovarian, pancreatic and other cancers. Not available in all countries.
The addition of Riskguard germline testing in combination with the OncoExTra test provides comprehensive answers for advanced cancer patients, providing both inherited (germline) and tumor (somatic) information in accordance with guidelines.
References:
4. Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 2006;24(23):3726-3734.
5. Albain KS, Barlow WE, Shak S, et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. The Lancet Oncology. 2010;11(1):55-65.
Early detection
The first step in changing the way we see cancer? Detecting it earlier. Our screening tests deliver earlier answers to drive life-saving actions. Not available outside the United States.
THE AT-HOME STOOL DNA TEST
The only noninvasive, FDA-approved colorectal cancer screening test that looks for multiple abnormal biomarkers, including DNA and blood in stool, Cologuard® finds colon cancer even in early stages when it is more treatable.* 1, 2, 3 Not available outside the United States.
EARLY-STAGE LIVER CANCER DETECTION
A sophisticated, yet simple, single blood test, the Oncoguard® Liver solution delivers advanced sensitivity and specificity to aid consistent and reliable hepatocellular cancer detection. Not available outside the United States.
*Based on 5-year relative survival.
References:
1. Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med. 2014;370(14):1287-1297.
2. Cologuard Clinician Brochure. Exact Sciences Corporation. Madison, WI.
3. American Cancer Society. Survival rates for colorectal cancer. Accessed April 28, 2023. https://www.cancer.org/cancer/colon-rectal-cancer/detection-diagnosis-staging/survival-rates.html
Innovation
The future depends on today’s accomplishments. Our team of innovators are constantly working to develop life-changing solutions in cancer screening and diagnostics.
COLORECTAL SCREENING
Cologuard® 2.0
Building on the success of Cologuard, the development of Cologuard 2.0 aims to preserve the convenience of an at-home stool DNA test while enhancing test performance with the goal of improving patient experience.
Colorectal Cancer Blood
To provide more options for the 44 million Americans who remain unscreened,6 Exact Sciences is developing a blood-based screening method for colorectal cancer to give you and your patients more choices.
EARLIER CANCER DETECTION
Multi-Cancer Early Detection (MCED)
Early cancer detection can allow for more effective treatment, yet gaps in cancer screening exist.7 Our innovative multi-biomarker class approach to MCED testing is being developed to detect a variety of tumor markers associated with multiple cancer types prior to symptom onset—all from a single blood draw. As part of routine care, MCED testing may help shift the paradigm in cancer screening.
Join us for an MCED breakout session on June 4th. Full event details below.
EARLIER RECURRENCE DETECTION
MRD Screening
The technologies in this section are under development. The features described are current development goals. They have not been cleared or approved by the US Food and Drug Administration or any other national regulatory authority.
References:
6. Piscitello A, Edwards DK. Estimating the screening-eligible population size, ages 45–74, at average risk to develop colorectal cancer in the United States. Cancer Prev Res (Phila). 2020;13(5):443-448.
7. Siegel RL Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17-48.
